CME Group Inc. (CME) fair value analysis
S&P 500 & Nasdaq · Updated 2026-10-19
CME price how computed
Forward Fair Value verdict
Fairly valuedCME is trading at within about 10% of estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $280.56
- Sector
- Financial Services
- 12-month range
- $218.58–$326.46
- Market cap
- $101B
- From 52-week high
- -14.1%
- Shares outstanding
- 360M
- Rank in Financial Services by discount to fair value
- #84 of 167
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
CME Group Inc. is a leading global derivatives marketplace that operates electronic trading platforms and clearinghouses for futures, options, and other derivatives contracts across multiple asset classes including commodities, equities, interest rates, and foreign exchange. The company serves customers worldwide from its headquarters in Chicago and operates exchange and clearing services in multiple countries to facilitate price discovery and risk management for participants in global financial and commodity markets.
CME currently ranks #84 of 167 Financial Services stocks by discount to fair value. It has screened as Fairly valued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $101B
- P/E (trailing)
- 24x
- Revenue (TTM)
- $6.77B
- Net margin
- 63.1%
- EPS (TTM)
- $11.80
- Gross margin
- 69.2%
- Debt / equity
- 0.13
- Revenue growth (3-yr avg)
- 9.2%
- Shares outstanding
- 360M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Contracting
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 70 · overbought
- 50-day average
- $273.77
- 200-day average
- $278.69
- Moving-average state
- 50-day below 200-day (death cross state); price between the averages
Dividends how computed
- Paid, last 12 months
- $11.30 per share (4 payments)
- Yield on last price
- 4.03%
- Consecutive years of increases
- 0 (no streak on complete calendar years)
- Last ex-dividend date
- 2026-09-09
- Last payment date
- 2026-09-25
Earnings how computed
- Last 8 quarters vs consensus
- 6 beat, 2 missed
- Quarter by quarter
- 2026-06 ▲ beat (+2.7%)
2026-03 ▼ miss (-0.3%)
2025-12 ▲ beat (+1.1%)
2025-09 ▲ beat (+1.9%)
2025-06 ▲ beat (+1.4%)
2025-03 ▼ miss (-0.4%)
2024-12 ▲ beat (+3.1%)
2024-09 ▲ beat (+1.1%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 8 buy · 5 hold · 3 sell (16 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $293
- Target vs last price
- +4.4%
What our data shows for CME
- Our model validated 17 trailing price-to-earnings windows for CME, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $218.58–$326.46.
- The 14-day relative strength index sits at an overbought 70.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for CME
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent CME news
TickrTrends' derived news-sentiment signal for CME is currently leaning positive, computed from recent coverage.
- Nasdaq (NDAQ) Can Index Growth Hold Up Without a Rising Market? (insidermonkey.com, 2026-10-14)
TickrTrends take: CME operates in the Financial Services sector alongside index providers like Nasdaq, and both companies benefit from market activity and trading volumes that tend to correlate with broader market movements. A valuation-focused reader watching CME at its current fairly valued assessment should monitor whether index-related revenue streams across the financial services industry can maintain growth momentum if equity markets stall, as this could pressure margin expansion and fee income for derivative exchange operators. CME's performance will likely depend on whether trading volatility and hedging activity continue to generate offsetting revenue even if the overall market lacks upward momentum. - CME Group: I Missed The Best Entry (NASDAQ:CME) (seekingalpha.com, 2026-10-10)
TickrTrends take: CME Group operates in the Financial Services sector and is currently assessed as fairly valued according to TickrTrends analysis. The headline's reflection on missed entry points suggests market participants continue to evaluate timing around the stock, which remains relevant for investors monitoring valuation dynamics in a mature financial exchange operator. For valuation-focused readers, tracking whether CME maintains its fairly valued designation will depend on how earnings trends and market structure changes affect the company's fundamental metrics relative to peers. - CME Group Heading Into Q3 With Solid Results But No Clear Re-Rating Catalyst (NASDAQ:CME) (seekingalpha.com, 2026-10-08)
TickrTrends take: CME Group's solid operational performance entering the third quarter supports its current fairly valued assessment, though investors focused on valuation catalysts should monitor whether management identifies new growth drivers that could justify multiple expansion. The Financial Services sector's competitive dynamics mean that without a clear re-rating catalyst, CME may continue trading in line with its fundamentals rather than commanding a valuation premium. Valuation-conscious investors should track earnings growth trajectories and market share developments that could shift the fairly valued designation in either direction.
More CME news
- CME Adds Bitcoin Cash, Uniswap Futures on Oct. 19 (financefeeds.com, 2026-09-22)
What people are saying
Follow the CME conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for CME show a shift in momentum this week, with the RSI zone moving from neutral into overbought territory. At its current valuation level of fairly valued, this overbought reading suggests the stock has experienced strong upward price movement over the recent period.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — CME's sector discount rank declined this week, moving from number 69 to number 76 among Financial Services companies. This shift indicates the stock has become relatively less discounted compared to its sector peers. The current valuation verdict remains Fairly valued.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is CME stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), CME is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.
What is CME's TickrTrends verdict?
CME's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.
How does CME compare to other Financial Services stocks?
CME ranks #84 of 167 Financial Services stocks in TickrTrends' coverage by discount to fair value.
Is CME overbought or oversold?
CME's 14-day RSI is in the overbought zone on TickrTrends' latest weekly data.
Does CME pay a dividend?
Yes. CME paid $11.30 per share over the last twelve months (4 payments), a 4.03% yield on TickrTrends' last price. The last ex-dividend date was 2026-09-09.
Does CME usually beat earnings estimates?
Over its last 8 reported quarters CME beat the consensus estimate 6 times and missed 2 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about CME?
Of 16 analysts covering CME, 8 rate it a buy, 5 a hold and 3 a sell - buy-leaning, with a consensus price target of $293 (+4.4% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Financial Services
Head-to-head comparisons
CME vs BOKF · CME vs DGICA · CME vs GL · CME vs HOPE · CME vs MET